Overview

Gender

male

Investor Type

Investment Partner

Charles Homcy is a partner at Third Rock Ventures, where he focuses on the formation of companies that discover and develop novel therapeutic approaches. He brings significant experience building and leading successful biotech companies and has played an integral role in the launching and building of Third Rock Ventures’ portfolio companies, including Ambys Medicines, Global Blood Therapeutics, Pliant Therapeutics, Relay Therapeutics, Goldfinch Bio, CytomX and MyoKardia.
Prior to Third Rock Ventures, Charles co-founded Portola Pharmaceuticals, where he served as president and CEO. Earlier, he served as president of research and development at Millennium, following the company’s acquisition of COR Therapeutics in 2002. Charles joined COR in 1995 as executive vice president of research and development and served as a director of the company from 1998 to 2002. From 1997 to 2008 Charles was a clinical professor of medicine at the University of California, San Francisco Medical School and an attending physician at the San Francisco VA Hospital. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories. Charles currently serves on the boards of Portola Pharmaceuticals, Ambys Medicines, Global Blood Therapeutics and Pliant Therapeutics.

Charles holds an A.B. and M.D. from Johns Hopkins University, where he presently serves on the board of trustees.